# Southeast Asia Dose Optimization of Tafenoquine

> **NCT04704999** · PHASE4 · RECRUITING · sponsor: **University of Oxford** · enrollment: 700 (estimated)

## Conditions studied

- Plasmodium Vivax Malaria

## Interventions

- **DRUG:** Tafenoquine
- **DRUG:** Chloroquine
- **DRUG:** Artemether 20 mg-Lumefantrine 120 mg

## Key facts

- **NCT ID:** NCT04704999
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-22
- **Primary completion:** 2027-10-04
- **Final completion:** 2028-02-07
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04704999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04704999, "Southeast Asia Dose Optimization of Tafenoquine". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT04704999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*